MENY

Gällande vårdprogram Hodgkins lymfom

Fastställt av Regionala cancercentrum i samverkan 2019-09-10.

22. Referenser

Abrahamsen, A. F., Loge, J. H., Hannisdal, E., Nome, O., Lund, M. B., Holte, H., & Kvaloy, S. (1999). Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol, 38(4), 511-515. 

Adams, H. J. A., & Kwee, T. C. (2016). Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. Eur J Radiol, 85(11), 1963-1970. doi:10.1016/j.ejrad.2016.08.011

Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol, 32(9), 912-918. doi:10.1200/JCO.2013.53.2069

Agarwal, A., Ranganathan, P., Kattal, N., Pasqualotto, F., Hallak, J., Khayal, S., & Mascha, E. (2004). Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril, 81(2), 342-348. doi:10.1016/j.fertnstert.2003.07.021

Altieri, A., & Hemminki, K. (2006). The familial risk of Hodgkin's lymphoma ranks among the highest in the Swedish Family-Cancer Database. Leukemia, 20(11), 2062-2063. doi:10.1038/sj.leu.2404378

Andersson, A., Naslund, U., Tavelin, B., Enblad, G., Gustavsson, A., & Malmer, B. (2009). Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention. Int J Cancer, 124(8), 1914-1917. doi:10.1002/ijc.24147

Ansell, S. M. (2012). Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol, 87(12), 1096-1103. doi:10.1002/ajh.23348

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., . . . Armand, P. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311-319. doi:10.1056/NEJMoa1411087

Armand, P., Shipp, M. A., Ribrag, V., Michot, J. M., Zinzani, P. L., Kuruvilla, J., . . . Moskowitz, C. H. (2016). Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. doi:10.1200/JCO.2016.67.3467

Bai, C. Z., Ji, H. J., Feng, M. L., Hao, X. L., Zhong, Q. M., Cui, X. D., & Wang, Z. H. (2015). Stimulation of dendritic cell maturation and induction of apoptosis in lymphoma cells by a stable lectin from buckwheat seeds. Genet Mol Res, 14(1), 2162-2175. doi:10.4238/2015.March.27.3

Banakh, I., Lam, A., Tiruvoipati, R., Carney, I., & Botha, J. (2016). Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review. Clin Case Rep, 4(5), 486-490. doi:10.1002/ccr3.549

Barrington, S. F., Kirkwood, A. A., Franceschetto, A., Fulham, M. J., Roberts, T. H., Almquist, H., . . . Johnson, P. W. (2016). PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 127(12), 1531-1538. doi:10.1182/blood-2015-11-679407

Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S. P., . . . Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol, 32(27), 3048-3058. doi:10.1200/JCO.2013.53.5229

Baudino, B., D'Agata, F., Caroppo, P., Castellano, G., Cauda, S., Manfredi, M., . . . Bisi, G. (2012). The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging, 56(6), 559-568. 

Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., . . . Arbeitsgemeinschaft Medikamentose, T. (2015). Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, 385(9976), 1418-1427. doi:10.1016/S0140-6736(14)61469-0

Behringer, K., Mueller, H., Goergen, H., Thielen, I., Eibl, A. D., Stumpf, V., . . . Borchmann, P. (2013). Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol, 31(2), 231-239. doi:10.1200/JCO.2012.44.3721

Biccler, J. L., Glimelius, I., Eloranta, S., Smeland, K. B., Brown, P. N., Jakobsen, L. H., . . . Smedby, K. E. (2019). Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin Oncol, 37(9), 703-713. doi:10.1200/jco.18.01652

Boll, B., Goergen, H., Behringer, K., Brockelmann, P. J., Hitz, F., Kerkhoff, A., . . . Borchmann, P. (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 127(18), 2189-2192. doi:10.1182/blood-2015-11-681064

Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., . . . Engert, A. (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), 2790-2802. doi:10.1016/s0140-6736(17)32134-7

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Canellos, G. P., & Mauch, P. (2010). What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol, 28(1), e8. doi:10.1200/JCO.2009.26.3293

Caporaso, N. E., Goldin, L. R., Anderson, W. F., & Landgren, O. (2009). Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma. Cancer J, 15(2), 117-123. doi:10.1097/PPO.0b013e3181a39585

Carbone, A., Spina, M., Gloghini, A., & Tirelli, U. (2011). Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol, 86(2), 170-179. doi:10.1002/ajh.21910

Carnevale-Schianca, F., Gallo, S., Rota-Scalabrini, D., Sangiolo, D., Fizzotti, M., Caravelli, D., . . . Grignani, G. (2011). Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol, 29(24), e691-693. doi:10.1200/JCO.2011.35.6733

Casasnovas, R. O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., . . . Meignan, M. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol, 20(2), 202-215. doi:10.1016/s1470-2045(18)30784-8

Cerhan, J. R., & Slager, S. L. (2015). Familial predisposition and genetic risk factors for lymphoma. Blood, 126(20), 2265-2273. doi:10.1182/blood-2015-04-537498

Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., . . . Keynote. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol, 35(19), 2125-2132. doi:10.1200/JCO.2016.72.1316

Cheson, B. D. (2007). The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am, 21(5), 841-854. doi:10.1016/j.hoc.2007.06.011

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., . . . United Kingdom National Cancer Research, I. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 32(27), 3059-3068. doi:10.1200/JCO.2013.54.8800

Diepstra, A., Niens, M., Vellenga, E., van Imhoff, G. W., Nolte, I. M., Schaapveld, M., . . . Poppema, S. (2005). Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet, 365(9478), 2216-2224. doi:10.1016/S0140-6736(05)66780-3

Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., . . . Travis, L. B. (2002). Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol, 20(16), 3484-3494. 

Dunleavy, K., Grant, C., Eberle, F. C., Pittaluga, S., Jaffe, E. S., & Wilson, W. H. (2012). Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep, 7(3), 241-247. doi:10.1007/s11899-012-0130-5

Eichenauer, D. A., Engert, A., Andre, M., Federico, M., Illidge, T., Hutchings, M., . . . Group, E. G. W. (2014). Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25 Suppl 3, iii70-75. doi:10.1093/annonc/mdu181

Eichenauer, D. A., Fuchs, M., Pluetschow, A., Klimm, B., Halbsguth, T., Boll, B., . . . Engert, A. (2011). Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood, 118(16), 4363-4365. doi:10.1182/blood-2011-06-361055

El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bogsted, M., Bukh, A., . . . Hutchings, M. (2012). Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol, 30(36), 4508-4514. doi:10.1200/JCO.2012.42.4036

Enblad, G., Glimelius, B., & Sundstrom, C. (1991). Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol, 2(4), 297-302. 

Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., . . . Arbeitsgemeinschaft Medikamentose, T. (2012). Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379(9828), 1791-1799. doi:10.1016/S0140-6736(11)61940-5

Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., . . . Diehl, V. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med, 363(7), 640-652. doi:10.1056/NEJMoa1000067

Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., . . . Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol, 161(1), 76-86. doi:10.1111/bjh.12222

Fallah, M., Liu, X., Ji, J., Forsti, A., Sundquist, K., & Hemminki, K. (2014). Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol, 25(7), 1397-1404. doi:10.1093/annonc/mdu144

Fardet, L., Lambotte, O., Meynard, J. L., Kamouh, W., Galicier, L., Marzac, C., . . . Martinez, V. (2010). Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS, 24(9), 1299-1306. doi:10.1097/QAD.0b013e328339e55b

Ferme, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., . . . Trial, E.-G. H. (2007). Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med, 357(19), 1916-1927. doi:10.1056/NEJMoa064601

Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., . . . Levis, A. (2007). Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol, 25(24), 3746-3752. doi:10.1200/JCO.2007.11.6525

Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A., Capodanno, I., . . . Levis, A. (2006). The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 91(4), 475-481. 

Galper, S. L., Yu, J. B., Mauch, P. M., Strasser, J. F., Silver, B., Lacasce, A., . . . Ng, A. K. (2011). Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood, 117(2), 412-418. doi:10.1182/blood-2010-06-291328

Glimelius, I., & Diepstra, A. (2016). Novel treatment concepts in Hodgkin lymphoma. J Intern Med. doi:10.1111/joim.12582

Goldin, L. R., Bjorkholm, M., Kristinsson, S. Y., Turesson, I., & Landgren, O. (2009). Highly increased familial risks for specific lymphoma subtypes. Br J Haematol, 146(1), 91-94. doi:10.1111/j.1365-2141.2009.07721.x

Gustavsson, A., Eskilsson, J., Landberg, T., Svahn-Tapper, G., White, T., Wollmer, P., & Akerman, M. (1990). Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol, 1(5), 355-363. 

Hahn, E., Jiang, H., Ng, A., Bashir, S., Ahmed, S., Tsang, R., . . . Hodgson, D. (2017). Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. Int J Radiat Oncol Biol Phys, 98(5), 1116-1123. doi:10.1016/j.ijrobp.2017.03.026

Hancock, S. L., Donaldson, S. S., & Hoppe, R. T. (1993). Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol, 11(7), 1208-1215. 

Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993). Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst, 85(1), 25-31. 

Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339(21), 1506-1514. doi:10.1056/NEJM199811193392104

Haverkos, B. M., Abbott, D., Hamadani, M., Armand, P., Flowers, M. E., Merryman, R., . . . Devine, S. M. (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood, 130(2), 221-228. doi:10.1182/blood-2017-01-761346

Hjalgrim, H. (2012). On the aetiology of Hodgkin lymphoma. Dan Med J, 59(7), B4485. 

Hjalgrim, H., Askling, J., Pukkala, E., Hansen, S., Munksgaard, L., & Frisch, M. (2001). Incidence of Hodgkin's disease in Nordic countries. Lancet, 358(9278), 297-298. doi:10.1016/S0140-6736(01)05498-8

Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J. S., . . . Melbye, M. (2003). Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med, 349(14), 1324-1332. doi:10.1056/NEJMoa023141

Hjalgrim, H., Seow, A., Rostgaard, K., & Friborg, J. (2008). Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer, 123(3), 716-719. doi:10.1002/ijc.23504

Hodgson, D. C., Gilbert, E. S., Dores, G. M., Schonfeld, S. J., Lynch, C. F., Storm, H., . . . Travis, L. B. (2007). Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol, 25(12), 1489-1497. doi:10.1200/JCO.2006.09.0936

Hollander, P., Rostgaard, K., Smedby, K. E., Chang, E. T., Amini, R. M., de Nully Brown, P., . . . Hjalgrim, H. (2015). Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma. Am J Epidemiol, 182(7), 624-632. doi:10.1093/aje/kwv081

Horwich, A., & Swerdlow, A. J. (2004). Second primary breast cancer after Hodgkin's disease. Br J Cancer, 90(2), 294-298. doi:10.1038/sj.bjc.6601499

Hull, M. C., Morris, C. G., Pepine, C. J., & Mendenhall, N. P. (2003). Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA, 290(21), 2831-2837. doi:10.1001/jama.290.21.2831

Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., . . . Specht, L. (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107(1), 52-59. doi:10.1182/blood-2005-06-2252

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307. 

Jaffe, E. S. (2009). The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program, 523-531. doi:10.1182/asheducation-2009.1.523

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., . . . Barrington, S. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med, 374(25), 2419-2429. doi:10.1056/NEJMoa1510093

Johnston, P. B., Inwards, D. J., Colgan, J. P., Laplant, B. R., Kabat, B. F., Habermann, T. M., . . . Witzig, T. E. (2010). A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol, 85(5), 320-324. doi:10.1002/ajh.21664

Kamper-Jorgensen, M., Rostgaard, K., Glaser, S. L., Zahm, S. H., Cozen, W., Smedby, K. E., . . . Hjalgrim, H. (2013). Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol, 24(9), 2245-2255. doi:10.1093/annonc/mdt218

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/JCO.2007.13.3033

Kostakoglu, L., Goldsmith, S. J., Leonard, J. P., Christos, P., Furman, R. R., Atasever, T., . . . Coleman, M. (2006). FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer, 107(11), 2678-2687. doi:10.1002/cncr.22276

Lambertini, M., Del Mastro, L., Pescio, M. C., Andersen, C. Y., Azim, H. A., Jr., Peccatori, F. A., . . . Anserini, P. (2016). Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med, 14, 1. doi:10.1186/s12916-015-0545-7

Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., . . . Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7(11), 1630-1636. 

Lord, S. J., Lei, W., Craft, P., Cawson, J. N., Morris, I., Walleser, S., . . . Houssami, N. (2007). A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer, 43(13), 1905-1917. doi:10.1016/j.ejca.2007.06.007

Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., . . . American Society of Clinical, O. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31(19), 2500-2510. doi:10.1200/JCO.2013.49.2678

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Mack, T. M., Cozen, W., Shibata, D. K., Weiss, L. M., Nathwani, B. N., Hernandez, A. M., . . . Rappaport, E. B. (1995). Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med, 332(7), 413-418. doi:10.1056/NEJM199502163320701

Mahajan, N. (2015). Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci, 8(1), 3-13. doi:10.4103/0974-1208.153119

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter 102.

Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., & Ansell, S. M. (2005). Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 23(30), 7614-7620. doi:10.1200/JCO.2005.02.7243

Martis, N., & Mounier, N. (2012). Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep, 7(3), 228-234. doi:10.1007/s11899-012-0125-2

Meignan, M., Barrington, S., Itti, E., Gallamini, A., Haioun, C., & Polliack, A. (2014). Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma, 55(1), 31-37. doi:10.3109/10428194.2013.802784

Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., . . . Eastern Cooperative Oncology, G. (2012). ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med, 366(5), 399-408. doi:10.1056/NEJMoa1111961

Molin, D., Linderoth, J., & Wahlin, B. E. (2017). Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. Br J Haematol, 177(3), 449-456. doi:10.1111/bjh.14567

Moskowitz, A. J., Schoder, H., Yahalom, J., McCall, S. J., Fox, S. Y., Gerecitano, J., . . . Moskowitz, C. H. (2015). PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol, 16(3), 284-292. doi:10.1016/S1470-2045(15)70013-6

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., . . . Group, A. S. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 385(9980), 1853-1862. doi:10.1016/S0140-6736(15)60165-9

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., . . . Sweetenham, J. (2018). Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood, 132(25), 2639-2642. doi:10.1182/blood-2018-07-861641

Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., . . . Hodgson, D. C. (2008). Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma, 49(8), 1486-1493. doi:10.1080/10428190802140873

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Ng, A. K. (2011). Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol, 154(1), 23-31. doi:10.1111/j.1365-2141.2011.08713.x

Parikh, R. R., Grossbard, M. L., Harrison, L. B., & Yahalom, J. (2015). Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. Leuk Lymphoma, 1-8. doi:10.3109/10428194.2015.1065978

Petersen, P. M., Aznar, M. C., Berthelsen, A. K., Loft, A., Schut, D. A., Maraldo, M., . . . Specht, L. (2015). Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol, 54(1), 60-66. doi:10.3109/0284186X.2014.932435

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Pinnix, C. C., Smith, G. L., Milgrom, S., Osborne, E. M., Reddy, J. P., Akhtari, M., . . . Dabaja, B. (2015). Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys, 92(1), 175-182. doi:10.1016/j.ijrobp.2015.02.010

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525. 

Rancea, M., Monsef, I., von Tresckow, B., Engert, A., & Skoetz, N. (2013). High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev(6), CD009411. doi:10.1002/14651858.CD009411.pub2

Rios, A. (2014). HIV-related hematological malignancies: a concise review. Clin Lymphoma Myeloma Leuk, 14 Suppl, S96-103. doi:10.1016/j.clml.2014.06.020

Sasse, S., Alram, M., Muller, H., Smardova, L., Metzner, B., Doehner, H., . . . Borchmann, P. (2016). Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma, 57(5), 1067-1073. doi:10.3109/10428194.2015.1083561

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Sieniawski, M., Franklin, J., Nogova, L., Glossmann, J. P., Schober, T., Nisters-Backes, H., . . . Josting, A. (2007). Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol, 25(15), 2000-2005. doi:10.1200/JCO.2006.10.1386

Sieswerda, E., Postma, A., van Dalen, E. C., van der Pal, H. J., Tissing, W. J., Rammeloo, L. A., . . . Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology, G. (2012). The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol, 23(8), 2191-2198. doi:10.1093/annonc/mdr595

Sjövall, K. (2011). Patienters perspektiv och upplevelser av cancersjukdom och cancervård. In H. M. Thomé B. (Ed.), Perspektiv på onkologisk vård (pp. 131-148). Lund: Studentlitteratur.

Solanki, A. A., LeMieux, M. H., Chiu, B. C., Mahmood, U., Hasan, Y., & Koshy, M. (2013). Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy. PLoS One, 8(9), e75336. doi:10.1371/journal.pone.0075336

Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., . . . Ilrog. (2014). Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys, 89(4), 854-862. doi:10.1016/j.ijrobp.2013.05.005

Stamatoullas, A., Brice, P., Bouabdallah, R., Mareschal, S., Camus, V., Rahal, I., . . . Tilly, H. (2015). Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol, 170(2), 179-184. doi:10.1111/bjh.13419

Stensheim, H., Klungsoyr, K., Skjaerven, R., Grotmol, T., & Fossa, S. D. (2013). Birth outcomes among offspring of adult cancer survivors: a population-based study. Int J Cancer, 133(11), 2696-2705. doi:10.1002/ijc.28292

Strongman, H., Brown, A., Smeeth, L., & Bhaskaran, K. (2019). Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals. Br J Cancer. doi:10.1038/s41416-019-0401-1

Swerdlow, A. J., Cooke, R., Bates, A., Cunningham, D., Falk, S. J., Gilson, D., . . . Wales Hodgkin Lymphoma Follow-up, G. (2014). Risk of premature menopause after treatment for Hodgkin's lymphoma. J Natl Cancer Inst, 106(9). doi:10.1093/jnci/dju207

Thompson, C. A., Mauck, K., Havyer, R., Bhagra, A., Kalsi, H., & Hayes, S. N. (2011). Care of the adult Hodgkin lymphoma survivor. Am J Med, 124(12), 1106-1112. doi:10.1016/j.amjmed.2011.05.020

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Wallace, W. H., Thomson, A. B., Saran, F., & Kelsey, T. W. (2005). Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys, 62(3), 738-744. doi:10.1016/j.ijrobp.2004.11.038

van Hulst, R. A., Rietbroek, R. C., Gaastra, M. T., & Schlosser, N. J. (2011). To dive or not to dive with bleomycin: a practical algorithm. Aviat Space Environ Med, 82(8), 814-818. 

van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., . . . van Leeuwen, F. E. (2016). Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol, 34(3), 235-243. doi:10.1200/jco.2015.63.4444

van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., . . . van Leeuwen, F. E. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med, 175(6), 1007-1017. doi:10.1001/jamainternmed.2015.1180

Weibull, C. E., Eloranta, S., Smedby, K. E., Bjorkholm, M., Kristinsson, S. Y., Johansson, A. L., . . . Glimelius, I. (2016). Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. J Clin Oncol, 34(4), 337-344. doi:10.1200/JCO.2015.63.3446

Weibull, C. E., Johansson, A. L. V., Eloranta, S., Smedby, K. E., Bjorkholm, M., Lambert, P. C., . . . Glimelius, I. (2018). Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators. J Clin Oncol, 36(26), 2718-2725. doi:10.1200/jco.2018.78.3514

Weiss, A. J., Horowitz, S., & Lackman, R. D. (1999). Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol, 22(2), 193-195. 

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Vermaete, N., Wolter, P., Verhoef, G., & Gosselink, R. (2013). Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol, 92(8), 1007-1021. doi:10.1007/s00277-013-1689-1

Yildiz, F., Zengin, N., Engin, H., Gullu, I., Barista, I., Caglar, M., . . . Tekuzman, G. (2004). Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease. Int J Radiat Oncol Biol Phys, 60(3), 839-846. doi:10.1016/j.ijrobp.2004.04.002

Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol, 30(18), 2183-2189. doi:10.1200/JCO.2011.38.0410

Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., . . . Engert, A. (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol, 17(9), 1283-1294. doi:10.1016/S1470-2045(16)30167-X

Yri, O. E., Torfoss, D., Hungnes, O., Tierens, A., Waalen, K., Nordoy, T., . . . Kolstad, A. (2011). Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood, 118(26), 6769-6771. doi:10.1182/blood-2011-08-372649